Lv4
640 积分 2021-02-23 加入
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
21小时前
待确认
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
21小时前
已完结
Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis
2个月前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
4个月前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
7个月前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
7个月前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
7个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
7个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
7个月前
已完结
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
7个月前
已完结
皖公网安备34019202002308
